EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetics of the Novel Adenosine A 2A Antagonist/Inverse Agonist KW‐6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease

Tomonori Tayama, Hiroki Okada, Kotoko Ogawa, Douglas Marsteller, Hiroshi Maeda, Matthew W Hruska, Yoshiyuki Kagawa

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Tomonori Tayama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Adenosine A2 Receptor Antagonists, Healthy Volunteers, Models, Biological, Parkinson Disease. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KW‐6356 is a selective antagonist and inverse agonist of the adenosine A 2A receptor. The primary aim of the present analysis was to characterize the pharmacokinetics (PK) of KW‐6356 and its active metabolite M6 in healthy subjects and patients with Parkinson's disease (PD). We pooled concentration‐time data from healthy subjects and patients with PD who were administered KW‐6356. Using these data, we developed a population PK model by sequentially fitting the KW‐6356 parameters followed by the M6 parameters. A first‐order absorption with a 1‐compartment model for KW‐6356 and a 1‐compartment model for M6 best described the profiles. The covariates included in the final models were food status (fed/fasted/unknown) on first‐order absorption rate constant, baseline serum albumin level on apparent clearance of KW‐6356, and baseline body weight on apparent volume of distribution of KW‐6356 and apparent clearance of M6. No covariate had a clinically meaningful impact on KW‐6356 or M6 exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine A2 Receptor AntagonistsHealthy VolunteersModels, BiologicalParkinson DiseaseAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAdenosine A2 Receptor AgonistsAdministration, OralAntiparkinson AgentsDrug Administration ScheduleReceptor, Adenosine A2A

Stichwörter der Autor:innen

KW‐6356Parkinson's diseaseadenosine A2Aadenosine antagonistmetabolitepopulation pharmacokinetics

Substanzen

Adenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsAntiparkinson AgentsReceptor, Adenosine A2A

Autor:innen und Institutionen

  • Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan.
  • Laboratory of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Clinical Pharmacology, Kyowa Kirin, Inc., Princeton, NJ, USA.

Zitieren

APA

Tayama, T., Okada, H., Ogawa, K., Marsteller, D., Maeda, H., Hruska, M. W., & Kagawa, Y. (2024). Population Pharmacokinetics of the Novel Adenosine A 2A Antagonist/Inverse Agonist KW‐6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1359

Vancouver

Tayama T, Okada H, Ogawa K, Marsteller D, Maeda H, Hruska MW, et al. Population Pharmacokinetics of the Novel Adenosine A 2A Antagonist/Inverse Agonist KW‐6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1359

BibTeX
@article{Tayama2024,
  author = {Tayama, Tomonori and Okada, Hiroki and Ogawa, Kotoko and Marsteller, Douglas and Maeda, Hiroshi and Hruska, Matthew W and Kagawa, Yoshiyuki},
  title = {Population Pharmacokinetics of the Novel Adenosine A 2A Antagonist/Inverse Agonist KW‐6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1359}
}
Kostenlos starten →